Nature Reviews Drug Discovery

Article	Citations
Engineering precision nanoparticles for drug delivery	3967
Natural products in drug discovery: advances and opportunities	2505
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	1328
PROTAC targeted protein degraders: the past is prologue	1298
Trends in peptide drug discovery	1005
Noncoding RNA therapeutics — challenges and potential solutions	896
Emerging concepts in the science of vaccine adjuvants	761
Macrophages as tools and targets in cancer therapy	752
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	734
Kinase drug discovery 20 years after imatinib: progress and future directions	600
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	544
Strategies for delivering therapeutics across the blood–brain barrier	535
Targeting cancer metabolism in the era of precision oncology	523
Anti-obesity drug discovery: advances and challenges	479
Channelling inflammation: gasdermins in physiology and disease	416
Trends in kinase drug discovery: targets, indications and inhibitor design	410
Antisense technology: an overview and prospectus	371
Therapeutically harnessing extracellular vesicles	369
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	360
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	347
The clinical landscape for AAV gene therapies	334
FDA approves 100th monoclonal antibody product	328
Advances in covalent drug discovery	305
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	304
Targeting HER2-positive breast cancer: advances and future directions	296

Advances in TRP channel drug discovery: from target validation to clinical studies	293
Navigating CAR-T cells through the solid-tumour microenvironment	292
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	277
Targeted protein degraders crowd into the clinic	274
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	274
Beyond immune checkpoint blockade: emerging immunological strategies	266
Drugging p53 in cancer: one protein, many targets	263
Emerging therapeutic opportunities for integrin inhibitors	262
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	256
PI3K inhibitors are finally coming of age	252
Image-based profiling for drug discovery: due for a machine-learning upgrade?	249
Targeting RNA structures with small molecules	248
Identification of neoantigens for individualized therapeutic cancer vaccines	248
Therapeutic strategies for COVID-19: progress and lessons learned	245
Function and therapeutic value of astrocytes in neurological diseases	237
Pharmacological targeting of endoplasmic reticulum stress in disease	224
Protein arginine methylation: from enigmatic functions to therapeutic targeting	223
Circadian rhythm as a therapeutic target	210
Advances in targeting ‘undruggable’ transcription factors with small molecules	204
Therapeutic strategies targeting FOXO transcription factors	193
Antibody–drug conjugates come of age in oncology	181
Engineering living therapeutics with synthetic biology	176
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	173
The emerging role of mass spectrometry-based proteomics in drug discovery	169
Lipogenesis inhibitors: therapeutic opportunities and challenges	168
Targeting Notch in oncology: the path forward	166
Engineering the next generation of cell-based therapeutics	161
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	148
Drugging the efferocytosis process: concepts and opportunities	148
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	146
2020 FDA drug approvals	145
Immune targets for therapeutic development in depression: towards precision medicine	142
Modulating biomolecular condensates: a novel approach to drug discovery	142
The PROTACtable genome	141
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	140
Deuterium in drug discovery: progress, opportunities and challenges	137
Rational combinations of targeted cancer therapies: background, advances and challenges	134
Targeting replication stress in cancer therapy	131
Exosome-based candidates move into the clinic	121
Phenotypic drug discovery: recent successes, lessons learned and new directions	118
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	115
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	114
The glomerular filtration barrier: a structural target for novel kidney therapies	112
The promises and perils of psychedelic pharmacology for psychiatry	105
Improving target assessment in biomedical research: the GOT-IT recommendations	104
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	104
The therapeutic potential of targeting regulated non-apoptotic cell death	104
Antibodies to combat viral infections: development strategies and progress	100
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders	99
Avidity in antibody effector functions and biotherapeutic drug design	99

Applications of single-cell RNA sequencing in drug discovery and development	94
A tale of two antiviral targets — and the COVID-19 drugs that bind them	92
Targeting galectin-driven regulatory circuits in cancer and fibrosis	87
Trends in COVID-19 therapeutic clinical trials	87
2021 FDA approvals	85
Targeting angiogenesis in oncology, ophthalmology and beyond	84
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems	81
Trends in the approval of cancer therapies by the FDA in the twenty-first century	78
The glymphatic system: implications for drugs for central nervous system diseases	78
Double setback for ASO trials in Huntington disease	77
AI in small-molecule drug discovery: a coming wave?	75
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	75
Clinical development times for innovative drugs	72
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating	70
Engineering islets from stem cells for advanced therapies of diabetes	68
Emerging principles of cytokine pharmacology and therapeutics	68
Exercise mimetics: harnessing the therapeutic effects of physical activity	68
Ligand binding at the protein–lipid interface: strategic considerations for drug design	67
The evolving role of investigative toxicology in the pharmaceutical industry	67
2022 FDA approvals	65
Gene therapy community grapples with toxicity issues, as pipeline matures	65
Artificial intelligence for natural product drug discovery	65
The expanding role for small molecules in immuno-oncology	64
The oncology market for antibody–drug conjugates	64
What does AlphaFold mean for drug discovery?	59
Restoring IL-2 to its cancer immunotherapy glory	58
Strategies to access biosynthetic novelty in bacterial genomes for drug discovery	58
Bispecific antibodies in oncology	58
Pan-coronavirus vaccine pipeline takes form	57
Landscape of cancer cell therapies: trends and real-world data	55
Accelerating antiviral drug discovery: lessons from COVID-19	54
Addressing cancer’s grand challenges	54
Targeting receptor complexes: a new dimension in drug discovery	52
Thinking outside the box: non-canonical targets in multiple sclerosis	51
AAV-based in vivo gene therapy for neurological disorders	49
Harnessing the predictive power of preclinical models for oncology drug development	48
Top companies and drugs by sales in 2021	46
Base editors hit the clinic	46
Antibody–oligonucleotide conjugates enter the clinic	45
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders	44
Beyond PI3Ks: targeting phosphoinositide kinases in disease	44
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	43
Top companies and drugs by sales in 2020	42
Derivatization with fatty acids in peptide and protein drug discovery	42
Amplifying gene expression with RNA-targeted therapeutics	42
The present and future of bispecific antibodies for cancer therapy	41
Antimalarial drug discovery: progress and approaches	39
Predictive validity in drug discovery: what it is, why it matters and how to improve it	39
mRNA flu shots move into trials	39
Drug delivery systems for CRISPR-based genome editors	38
Adoption of organ-on-chip platforms by the pharmaceutical industry	38
Small-molecule discovery through DNA-encoded libraries	38
VEGFA mRNA for regenerative treatment of heart failure	37
Using human genetics to improve safety assessment of therapeutics	36
The landscape for lipid-nanoparticle-based genomic medicines	35
2023 FDA approvals	35
Delivering on the promise of protein degraders	35
Strategies to therapeutically modulate cytokine action	34
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs	33
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR	32
FDA approves first BCMA-targeted CAR-T cell therapy	30
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges	29
FDA approves fourth CAR-T cell therapy	29
Membrane transporters in drug development and as determinants of precision medicine	29
Therapeutic RNA-silencing oligonucleotides in metabolic diseases	29
The clinical pipeline for cancer cell therapies	29
Disease modification in inflammatory skin disorders: opportunities and challenges	28
Trends in oncology drug innovation in China	28
First de novo deuterated drug poised for approval	27
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	27
Author Correction: Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	27
Therapeutic approaches for Duchenne muscular dystrophy	27
Top companies and drugs by sales in 2022	26
The breast cancer drug market	26
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome	25
Characteristics of expedited programmes for cancer drug approval in China	25
Evolution of the market for mRNA technology	25
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	24
Application of Bayesian approaches in drug development: starting a virtuous cycle	24
Tailor made: the art of therapeutic mRNA design	24

The mRNA vaccine development landscape for infectious diseases	23
Strategies to reduce the risks of mRNA drug and vaccine toxicity	23
BCKDK: an emerging kinase target for metabolic diseases and cancer	23
COVID-19 impact on oncology clinical trials: a 1-year analysis	22
Targeting synapse function and loss for treatment of neurodegenerative diseases	22
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections	20
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm	20
NfL makes regulatory debut as neurodegenerative disease biomarker	20
The market for ulcerative colitis	19
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders	19
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing	18
The KRAS crowd targets its next cancer mutations	18
Extracellular targeted protein degradation: an emerging modality for drug discovery	18
RSV vaccines score landmark FDA approvals	17
Trends in innovative drug development in China	17
FDA approves second RNA aptamer	17
Implications of sex-related differences in central nervous system disorders for drug research and development	17
First CRISPR therapy seeks landmark approval	17
RAS-targeted therapies	17
eEF2K: an atypical kinase target for cancer	17
opnMe.com: a digital initiative for sharing tools with the biomedical research community	17
Industrializing engineered autologous T cells as medicines for solid tumours	16
ALS antisense drug falters in phase III	16
FDA approves second BCMA-targeted CAR-T cell therapy	16
FDA approves first haemophilia B gene therapy	15
The prostate cancer drug market	15
Research on rare diseases: ten years of progress and challenges at IRDiRC	14
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment	14
Evolution of innovative drug R&D in China	14
Genetic support for FDA-approved drugs over the past decade	14
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers	13
Small activating RNAs lead the charge to turn up gene expression	13
Trends in the use of liquid biopsy in oncology	13
Kinase drug discovery 20 years after imatinib	13
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease	13
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape	12
Comparing development strategies for PD1/PDL1-based immunotherapies	12
Targeted protein degraders: a call for collective action to advance safety assessment	12
Long COVID’s long R&D agenda	12
The next-generation CAR-T therapy landscape	12
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	11
Accelerating therapeutic discoveries for heart failure: a new public–private partnership	11
Targeting immunogenic cell stress and death for cancer therapy	11
Claudin-18.2 attracts the cancer crowd	11
Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design	11
Top product forecasts for 2022	11
tRNA therapeutics for genetic diseases	11
LRRK2-targeted Parkinson disease drug advances into phase III	11
LAG3 pushes immuno-oncology’s leading edge	10
CAR T cell therapies raise hopes — and questions — for lupus and autoimmune disease	10
Herding in the drug development pipeline	10
Personalized cancer vaccines pass first major clinical test	10
Climbing cancer’s MYC mountain	10
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	10
The non-small-cell lung cancer drug market	10
FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers	10
The malignant melanoma market	10
The R&D landscape for infectious disease vaccines	10
Trends in the global antibiotics market	9
RNAi-based drug design: considerations and future directions	9
Promoting efferocytosis heals diabetic wounds	9
Orphan drug designation and development in Japan: 25 years of experience and assessment	9
T cell receptor therapeutics hit the immuno-oncology stage	9
Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line	9
FDA approves antibody cocktail for Ebola virus	9
Biotechs step on cGAS for autoimmune diseases	8
The most successful oncology drug portfolios of the past decade	8
FDA approves first chikungunya vaccine	8
Translational misconceptions	8
Macrocycle drugs serve up new opportunities	8
Top product forecasts for 2023	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
Proximity-inducing drugs get closer	8
What’s next for the synthetic lethality drug discovery engine?	8
Lentiviral vector gene therapies come of age with two FDA approvals	8
FDA approves first cell therapy for type 1 diabetes	8
Novel drug targets in 2021	8
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor	8
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities	8
Cartilage regeneration for osteoarthritis	7
Novel drug targets in 2020	7
Author Correction: PI3K inhibitors are finally coming of age	7
The significance of blockbusters in the pharmaceutical industry	7
FDA approves first all-oral sleeping sickness drug	7
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease	7
Targeting the mitochondria to block tumour growth	7
A new route to regulating AMPK activity	7
Anti-tau antibody failures stack up	7
Screening ultra-large virtual libraries	7
Glue-based KRAS inhibitors make their debut cancer trial mark	7
Envisioning an actionable research agenda to facilitate repurposing of off-patent drugs	7
Advancing innovative clinical trials to efficiently deliver medicines to patients	7
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	7
eTRANSAFE: data science to empower translational safety assessment	7